MOAT
MOAT identifies genomic regions with an unexpectedly high mutation count to detect potential cancer driver mutations using a non-parametric, permutation-based approach.
Key Features:
- Non-parametric permutation testing: Uses permutation-based analysis that avoids explicit parametric modeling of background mutation rates.
- Background mutation rate assumption: Assumes the background mutation rate (BMR) varies smoothly with genomic features rather than requiring cell-type-matched covariates.
- Permutation targets: Performs large-scale random permutations of single-nucleotide variants or predefined target regions to assess mutation overburden.
- GPU acceleration: Employs graphics processing unit (GPU) acceleration to expedite permutations, achieving an approximately 250-fold speed-up compared to traditional methods.
- Robust burden analysis: Enables statistical assessment of mutation enrichment across genomic regions via extensive permutation sampling.
Scientific Applications:
- Cancer genomics: Identification of regions with mutation overburden to discover potential driver mutations involved in oncogenesis.
- Large-scale mutational landscape analysis: Application to large genomic datasets where covariate-independent burden testing and rapid computation are required.
Methodology:
MOAT applies non-parametric, permutation-based analysis by performing large-scale random permutations of single-nucleotide variants or target regions under the assumption that BMR varies smoothly with genomic features, and uses GPU acceleration to speed permutations (≈250-fold).
Topics
Details
- License:
- Unlicense
- Maturity:
- Mature
- Cost:
- Free of charge
- Tool Type:
- command-line tool
- Operating Systems:
- Linux, Windows, Mac
- Added:
- 7/7/2019
- Last Updated:
- 6/16/2020
Operations
Data Inputs & Outputs
Publications
Lochovsky L, Zhang J, Gerstein M. MOAT: efficient detection of highly mutated regions with the Mutations Overburdening Annotations Tool. Bioinformatics. 2017;34(6):1031-1033. doi:10.1093/bioinformatics/btx700. PMID:29121169. PMCID:PMC5860157.
Funding: - National Institutes of Health: 5U41HG007000-04